Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis

被引:1
|
作者
Kawashima, Jun [1 ,2 ,3 ]
Akabane, Miho [1 ,2 ]
Endo, Yutaka [4 ]
Woldesenbet, Selamawit [1 ,2 ]
Altaf, Abdullah [1 ,2 ]
Ruzzenente, Andrea [5 ]
Popescu, Irinel [6 ]
Kitago, Minoru [7 ]
Poultsides, George [8 ]
Sasaki, Kazunari [8 ]
Aucejo, Federico [9 ]
Sahara, Kota [3 ]
Endo, Itaru [3 ]
Pawlik, Timothy M. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[2] James Comprehens Canc Ctr, Columbus, OH 43210 USA
[3] Yokohama City Univ, Sch Med, Dept Gastroenterol Surg, Yokohama, Japan
[4] Univ Rochester, Med Ctr, Dept Transplant Surg, Rochester, NY USA
[5] Univ Verona, Dept Surg, Verona, Italy
[6] Fundeni Clin Inst, Dept Surg, Bucharest, Romania
[7] Keio Univ, Dept Surg, Tokyo, Japan
[8] Stanford Univ, Dept Surg, Stanford, CA USA
[9] Cleveland Clin Fdn, Dept Gen Surg, Cleveland, OH USA
关键词
colorectal liver metastases; curative resection; hazard function; recurrence; PRACTICE GUIDELINE; HEPATIC RESECTION; TUMOR BURDEN; CANCER; HEPATECTOMY; SURVIVAL; CLASSIFICATION; SURVEILLANCE; PROPOSAL; SURGERY;
D O I
10.1002/jso.28007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionThere is no consensus on the optimal surveillance interval for patients undergoing resection of colorectal liver metastases (CRLM). We sought to assess the timing and intensity of recurrence following curative-intent resection of CRLM utilizing a recurrence-free survival (RFS) hazard function analysis.MethodsPatients with CRLM who underwent curative-intent resection were identified from a multi-institutional database. The RFS hazard function was used to plot hazard rates and identify the peak of recurrence over time.ResultsAmong 1804 patients, the median RFS was 19.9 months. In the analytic cohort, the RFS hazard curve peaked at 5.9 months (peak hazard rate: 0.054) and gradually declined, indicative of early recurrence. In subgroup analyses, patients with high and medium tumor burden scores (TBS) had RFS hazard peaks at 4.9 months (peak hazard rate: 0.060) and 5.8 months (peak hazard rate: 0.054), respectively. In contrast, patients with low TBS had a later peak at 7.5 months, with the lowest peak hazard rate of 0.047.ConclusionsThe recurrence peak for CRLM patients occurred approximately 6 months postsurgery, highlighting the need for intensified early postoperative surveillance. Patients with high TBS experienced earlier recurrence, underscoring the importance of close monitoring, particularly during the first 6 months after surgery.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Timing of Resection for Synchronous Liver Metastases from Colorectal Cancer
    Kaibori, Masaki
    Iwamoto, Shigeyoshi
    Ishizaki, Morihiko
    Matsui, Kosuke
    Saito, Takamichi
    Yoshioka, Kazuhiko
    Hamada, Yoshinori
    Kwon, A. Hon
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (11) : 3262 - 3270
  • [2] Recurrence patterns predict survival after resection of colorectal liver metastases
    Wong, Geoffrey Yuet Mun
    Mol, Barend
    Bhimani, Nazim
    de Reuver, Philip
    Diakos, Connie
    Molloy, Mark P.
    Hugh, Thomas J.
    ANZ JOURNAL OF SURGERY, 2022, 92 (09) : 2149 - 2156
  • [3] Recurrence of liver metastases from colorectal cancer and repeat liver resection
    Navarro Freirei, Francisco
    Navarro Sanchez, Patricia
    Miron Pozo, Benito
    Teresa Delgado Urena, Maria
    Antonio Jimenez Rios, Jose
    Antonio Garcia Lopez, Pedro
    Ignacio Arcelus Martinez, Juan
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2015, 107 (12) : 732 - 739
  • [4] Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases
    Yamashita, Yo-ichi
    Adachi, Eisuke
    Toh, Yasushi
    Ohgaki, Kippei
    Ikeda, Osamu
    Oki, Eiji
    Minami, Kazuhito
    Sakaguchi, Yoshihisa
    Tsujita, Eiji
    Okamura, Takeshi
    SURGERY TODAY, 2011, 41 (04) : 526 - 532
  • [5] Survival by Number and Sites of Resections of Recurrence after First Curative Resection of Colorectal Liver Metastases
    Panettieri, Elena
    Kim, Bradford J.
    Kawaguchi, Yoshikuni
    Ardito, Francesco
    Mele, Caterina
    De Rose, Agostino Maria
    Vellone, Maria
    Chun, Yun Shin
    Tzeng, Ching-Wei D.
    Aloia, Thomas A.
    Giuliante, Felice
    Vauthey, Jean-Nicolas
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2503 - 2511
  • [6] Prognostic factors associated with early recurrence following liver resection for colorectal liver metastases: a systematic review and meta-analysis
    Tian, Yuan
    Wang, Yaoqun
    Wen, Ningyuan
    Wang, Shaofeng
    Li, Bei
    Liu, Geng
    BMC CANCER, 2024, 24 (01)
  • [7] Recurrence patterns after laparoscopic resection of colorectal liver metastases
    Tabchouri, Nicolas
    Gayet, Brice
    Okumura, Shinya
    Donatelli, Gianfranco
    Beaussier, Marc
    Bennamoun, Mostefa
    Louvet, Christophe
    Fuks, David
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2018, 32 (12): : 4788 - 4797
  • [8] Risk factors for survival following recurrence after first liver resection for colorectal cancer liver metastases
    Serrano, Pablo E.
    Gu, Chu-Shu
    Husien, Mohamed
    Jalink, Diederick
    Ritter, Anne
    Martel, Guillaume
    Tsang, Melanie E.
    Law, Calvin H.
    Hallet, Julie
    McAlister, Vivian
    Sela, Nathalie
    Solomon, Hannah
    Moulton, Carol-Anne
    Gallinger, Steven
    Levine, Mark
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (08) : 1420 - 1426
  • [9] Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases
    Takeda, Kazuhisa
    Kikuchi, Yutaro
    Sawada, Yu
    Kumamoto, Takafumi
    Watanabe, Jun
    Kuniski, Chikara
    Misumi, Toshihiro
    Endo, Itaru
    ANTICANCER RESEARCH, 2022, 42 (11) : 5497 - 5505
  • [10] Patterns and Predictors of Recurrence After Curative Resection of Colorectal Liver Metastasis (CRLM)
    Vadisetti, Satya Niharika
    Kazi, Mufaddal
    Patkar, Shraddha
    Mundhada, Rohit
    Desouza, Ashwin
    Saklani, Avanish
    Goel, Mahesh
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) : 1559 - 1568